Published on Jul 21, 2017 Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses CAR T-cell therapy for patients with head and neck …
VIDEO: CAR T-Cell Therapy in Head and Neck Cancer Read More
July 3, 2017 (Medical News Today) Overall, the immune system does a remarkable job defending the body from disease-causing agents. When it comes to cancer, however, it falls short. Niroshana …
New insights into why the immune system fails to see cancer Read More
December 29, 2016 (HealthDay News) Tumors regressed after intracranial infusions of T cells engineered to target tumor-associated antigen Treatment with autologous chimeric antigen receptor (CAR)-engineered T cells targeting the tumor-associated …
Case Report: Adoptive T-Cell Tx Shows Promise in Glioblastoma Read More
The manufacturing process for CAR-T cells is similar, even though the design and structure of the tumor specific scFv (single chain fragment variable) may be proprietary. The methods used to …
CAR T-Cell Therapy HCP Guide – Quality and Education: Necessary Steps Read More
What are present hurdles faced with chimeric antigen receptor-engineered T cells (CAR-T cells) therapy? A. Antigen loss relapse B. On target/off tumor toxicity C. Less efficacy in solid tumors D. …
StatPearls Question of the Week – #9 Read More
In the manufacturing facility the CAR structure is synthesized using the patient’s own T-cells. The CAR is a fusion protein that contains 3 distinct functional domains. For example, with axicabtagene …
CAR T-Cell Therapy HCP Guide – CAR Structure Read More
Before the bioengineered T-cells are reinfused, the patient undergoes a conditioning chemotherapy regimen to reduced the competing T-cell population (lymphodepletion), lower the tumor burden and help reduce serious complications such …
CAR T-Cell Therapy HCP Guide – Patient Delivery: The Preinfusion Conditioning Regime Read More
CAR T-cell therapy is not yet approved by the FDA and is considered investigational; a patient must enter a clinical trial to receive it. Here’s the process: Leukapheresis: The patient’s …
CAR T-Cell Therapy HCP Guide – How Are CAR T-Cells Manufactured? Read More
Axicabtagene ciloleucel (KTE-C19) from Kite Pharma was the first CAR T-cell therapy submitted to the FDA for approval in March 2017. For the current submission, axicabtagene ciloleucel has been studied …
CAR T-Cell Therapy HCP Guide – CAR T-Cell Therapy at the FDA Read More
July 6, 2017 (ecancer) Dr Lin speaks with ecancer at EHA 2017 about clinical and biologic outcomes in patients with refractory aggressive Non-Hodgkin Lymphoma (NHL) treated with CAR T cell …
VIDEO: ZUMA1 trial of CD19 CAR T cells for aggressive NHL Read More